Osteoarthritis: Can anti-cytokine therapy play a role in treatment?

Clinical Rheumatology

Volumn 29, Issue 5, 2010, Pages 451-455

  Calich, Ana Luisa G ^a   Domiciano, Diogo S ^a   Fuller, Ricardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

IL 1; Inflammation; Osteoarthritis; TNF alpha

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DIACETYLRHEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TANEZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

CARTILAGE DEGENERATION; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; EXPERIMENTAL MODEL; GENE THERAPY; HUMAN; IN VITRO STUDY; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; KNEE PAIN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-1BETA; MODELS, BIOLOGICAL; OSTEOARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950864738     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1352-3     Document Type: Review

References (41)

1. JS Kramer EH Yelin WV Epstein 1983 Social and economic impacts of four musculoskeletal conditions: a study using national community-based data J Rheumatol 26 901 907 1:STN:280:DyaL3s3ls1OgtA%3D%3D
2. E Levy A Ferme D Perocheau I Bono 1993 Socioeconomic costs of osteoarthritis in France Rev Rheum 60 63S 67S 1:STN:280:DyaK2c7mtlWktA%3D%3D
3. JP Pelletier J Martel-Pelletier SB Abramson 2001 Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets Arthritis Rheum 44 6 1237 1247 10.1002/1529-0131(200106)44:6<1237:: AID-ART214>3.0.CO;2-F 1:STN:280:DC%2BD3MzksVOhug%3D%3D 11407681 (Pubitemid 32537520)
4. HJ Mankin H Dorfman L Lippiello A Zarins 1971 Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic hips. II. Correlation of morphology with biochemical and metabolic data J Bone Joint Surg Am 53 523 537 1:CAS:528:DyaE3MXktFOmtrg%3D 5580011
5. G Meachim GV Osborne 1970 Repair at the femoral articular surface in osteo-arthritis of the hip J Pathol 102 1 8 10.1002/path.1711020102 1:STN:280:DyaE3M7jvFGqsg%3D%3D 4101024
6. A Shibakawa H Aoki K Masuko-Hongo T Kato, et al. 2003 Presence of pannus-like tissue on osteoarthritic cartilage and its histological character Osteoarthritis Cartilage 11 133 140 10.1053/joca.2002.0871 1:STN:280: DC%2BD3s%2FksFGksA%3D%3D 12554129 (Pubitemid 36221649)
7. LI Sakkas C Scanzello N Johanson J Burkholder, et al. 1998 T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis Clin Diagn Lab Immunol 5 4 430 437 1:CAS:528:DyaK1cXltVOrt70%3D 9665944 (Pubitemid 28342865)
8. M Sharif L Shepstone CJ Elson PA Dieppe JR Kirwan 2000 Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee Ann Rheum Dis 59 71 74 10.1136/ard.59.1.71 1:CAS:528:DC%2BD3cXhtVWhsLk%3D 10627432 (Pubitemid 30303902)
9. D Loeuille I Chary-Valckenaere J Champigneulle AC Rat F Toussaint, et al. 2005 Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee. Correlating magnetic resonance imaging findings with disease severity Arthritis Rheum 52 11 3492 3501 10.1002/art.21373 16255041 (Pubitemid 41612215)
10. J Bondeson SD Wainwright S Lauder N Amos, et al. 2006 The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis Arthritis Research & Therapy 8 6 1 12 10.1186/ar2099 (Pubitemid 46211006)
11. JP Pelletier MP Faure JA DiBattista S Wilhelm D Visco J Martel-Pelletier 1993 Coordinate synthesis of stromelysin, interleukin-1, and oncogene proteins in experimental osteoarthritis. An immunohistochemical study Am J Pathol 142 95 105 1:CAS:528:DyaK3sXks12lsbw%3D 8424468 (Pubitemid 23026914)
12. MB Goldring 1999 The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models Connect Tissue Res 40 1 11 10.3109/03008209909005273 1:CAS:528:DyaK1MXjtFKktbo%3D 10770646 (Pubitemid 29139343)
13. JF Schlaak A Schwarting P Knolle KH Meyer zum Buschenfelde, et al. 1995 Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts Ann Rheum Dis 54 560 565 10.1136/ard.54.7.560 1:CAS:528:DyaK2MXns1Clt70%3D 7668899
14. MB Goldring LJ Sandel ML Stephenson SM Krane 1996 Immune interferon suppresses levels of procollagen in mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes J Biol Chem 261 9049 9056
15. C Jacques G Bereziat L Humbert M Corvol JL Olivier J Masliah, et al. 1997 Post-transcriptional effect of IGF-I on IL-1-induced type II secreted phospholipase A2 gene expression in rabbit articular chondrocytes J Clin Invest 99 1864 1872 10.1172/JCI119353 1:CAS:528:DyaK2sXisF2qt70%3D 9109430
16. RM Clancy AR Amin SB Abramsom 1998 The role of nitric oxide in inflammation and immunity Arthritis Rheum 41 1141 1151 10.1002/1529-0131(199807) 41:7<1141::AID-ART2>3.0.CO;2-S 1:CAS:528:DyaK1cXkslWjtL4%3D 9663469 (Pubitemid 28313414)
17. M Lotz 1999 The role of nitric oxide in articular cartilage damage Rheum Dis Clin North Am 25 269 282 10.1016/S0889-857X(05)70067-3 1:STN:280: DyaK1M3osV2jtw%3D%3D 10356417 (Pubitemid 29267883)
18. MB Goldring F Berembaum 1999 Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression Osteoarthritis Cartilage 7 386 388 10.1053/joca.1998.0219 1:STN:280:DyaK1MzltVyjsw%3D%3D 10419775 (Pubitemid 29331556)
19. J Martel-Pelletier R McCollum J DiBattista M-P Faure JA Chin S Fournier, et al. 1992 The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes: identification as the type I receptor and analysis of binding kinetics and biologic function Arthritis Rheum 35 530 540 10.1002/art.1780350507 1:CAS:528:DyaK38Xls12hurs%3D 1533521
20. E Hedbom HJ Hauselmann 2002 Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation Cell Mol Life Sci 59 45 53 10.1007/s00018-002-8404-z 1:CAS:528:DC%2BD38XhtVSnsLc%3D 11846032 (Pubitemid 34117355)
21. J Martel-Pelletier N Alaaeddine JP Pelletier 1999 Cytokines and their role in pathophysiology of osteoarthritis Front Biosci 4 694 703 10.2741/Martel
22. T Shalom-Barak J Quach M Lotz 1998 Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activation protein kinases and NF-kB J Biol Chem 273 27467 27473 10.1074/jbc.273.42.27467 1:CAS:528:DyaK1cXntVShu7s%3D 9765276 (Pubitemid 28500465)
23. T Olee S Hashimoto J Quach M Lotz 1999 IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses J Immunol 162 1096 1100 1:CAS:528:DyaK1MXovFyitQ%3D%3D 9916738 (Pubitemid 29035439)
24. WP Arend JM Dayer 1995 Inhibition of the production and effects of interleukin-1 and tumor necrosis alpha in rheumatoid arthritis Arthritis Rheum 38 151 160 10.1002/art.1780380202 1:STN:280:DyaK2M7ltFSnsA%3D%3D 7848304
25. EC Arner RR Harris TM DiMeo RC Collins W Galbraith 1995 Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit J Rheumatol 22 1338 1346 1:CAS:528:DyaK2MXntV2qurg%3D 7562769
26. WP Arend 1993 Interleukin-1 receptor antagonist Adv Immunol 54 167 227 10.1016/S0065-2776(08)60535-0 1:CAS:528:DyaK3sXms1yitb8%3D 8379462
27. JP Caron JC Fernandes J Martel-Pelletier, et al. 1996 Chondroprotective effect of intra-articular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression Arthritis Rheum 39 1535 1544 10.1002/art.1780390914 1:CAS:528:DyaK28XmsFCmt7s%3D 8814066 (Pubitemid 26314988)
28. JC Fernandes G Tardif J Martel-Pelletier, et al. 1999 In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthitic progression Am J Pathol 154 1535 1544 (Pubitemid 29169750)
29. JP Pelletier JP Caron C Evans, et al. 1997 In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy Arthritis Rheum 40 1012 1019 10.1002/art.1780400604 1:CAS:528: DyaK2sXktV2qsbc%3D 9182910 (Pubitemid 27242287)
30. DD Frisbie SC Ghivizzani PD Robbins CH Evans CW McIlwraith 2002 Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene Gene Ther 9 12 20 10.1038/sj.gt.3301608 1:CAS:528:DC%2BD38XhtV2iu78%3D 11850718
31. J Martel-Pelletier F Mineau FC Jolicoeur, et al. 1998 In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes J Rheumatol 25 753 762 1:CAS:528:DyaK1cXislahtb8%3D 9558181 (Pubitemid 28212387)
32. JP Pelletier N Yaron B Haraqui, et al. 2000 Efficacy and safety of diacerein in osteoarthritis of the knee: a double blind, placebo-control trial. The diacerein study group Arthritis Rheum 43 2339 2348 10.1002/1529-0131(200010) 43:10<2339::AID-ANR23>3.0.CO;2-P 1:CAS:528:DC%2BD3cXnslWjsLg%3D 11037895
33. M Dougados M Nguyen L Berdah, et al. 2003 Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip Clin Exp Rheumatol 21 152 154
34. X Chevalier B Girardeau T Conrozier J Marliere P Kiefer P Goupille 2005 Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study J Rheumatol 32 1317 1323 1:CAS:528:DC%2BD2MXnsl2nsL8%3D 15996071 (Pubitemid 40995389)
35. X Chevalier P Goupille AD Beaulieu FX Burch WG Bensen T Conrozier D Loeuille AJ Kivits D Silver BE Appleton 2009 Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study Artthritis Rheum 61 344 352 10.1002/art.24096 1:STN:280:DC%2BD1M7pt1Cktw%3D%3D
36. M Grunke H Schulze-Koops 2006 Successful treatment of inflammatory knee osteoarthritis with tumor necrosis factor blockade Ann Rheum Dis 65 555 556 10.1136/ard.2006.053272 1:STN:280:DC%2BD287ktFKisg%3D%3D 16531556
37. MD Magnano EF Chakravarty C Broudy L Chung A Kelman J Hillygus MC Genovese 2007 A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands J Rheumatol 34 1323 1327 1:CAS:528:DC%2BD2sXnvVems7Y%3D 17516620 (Pubitemid 46898115)
38. YN Abdiche DS Malashock J Pons 2008 Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors Protein Sci 17 1326 1335 10.1110/ps.035402.108 1:CAS:528:DC%2BD1cXpsVyju78%3D 18505735
39. Lane NE, Schnitzer TJ, Smith MD et al (2008) Tanezumab relieves moderate to severe pain due to osteoarthritis of the knee: a phase 2 trial. In: American College of Rheumatology. http://acr.confex.com/acr/2008/webprogram/Paper3546. html
40. Pfizer (2008) A phase 3 randomized, double blind, placebo-controlled multicenter study of the analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the knee. In: ClinicalTrials.gov. http://www. clinicaltrials.gov/show/NCT00733902. Accessed 4 Oct 2009
41. Pfizer (2008) A phase 3 randomized, double blind, placebo-controlled multicenter study of the analgesic efficacy and safety of tanezumab in patients with osteoarthritis of the hip. In: ClinicalTrials.gov. http://www. clinicaltrials.gov/show/NCT00744471. Acessed 4 Oct 2009